Table 1.
Enzyme | Level | Function | Pathology during Sepsis |
---|---|---|---|
LCAT | ↓ | Promotes cholesterol efflux from cells to nascent HDL [84] | Diminished adrenal glucocorticoid function [85] Reduced LPS-neutralizing ability of HDL [86] |
CETP | ↓ | Exchange of CE & TG between HDL and Apo-B-containing lipoproteins; promotes HDL maturation [87] | Missense variant in sepsis patients associated with HDL reduction, decreased survival, and increased organ failure [88] |
PLTP | ↑ | Transfer of amphipathic molecules including phospholipids [89] | Regulates HDL size and composition [90] Recombinant PLTP in mice decreases bacterial growth and accelerates LPS detoxification [91] |
PON | ↓ | Hydrolyzes lipid peroxides | Declines 71% in sepsis day 1–3 [92] Fails to inhibit oxLDL [93,94] |
PAF-AH | ↓ | Hydrolyzes PAF | Declines 90% in sepsis day 1–3 [92] Failure to hydrolyze PAF, leading to immune cell activation, platelet activation, vascular permeability, and hypotension [95] Recombinant PAF-AH had no mortality benefit when used in septic patients [96] |
EL | ↑ | Hydrolyzes HDL particles to liberate FFAs [97] | Upregulation leads to reduced HDL levels [98] Upregulation in inflammatory states may play a role in the resulting low-HDL state [99] EL knockout mice had increased survival to LPS-induced inflammation [100] |
SAA | ↑ | Cytokine-like, propagates APR, modifies HDL transport [101] | >1000-fold increase during APR, displacing Apo-A-I [102] Comprises up to 80% of the proteins in higher-density HDL molecules [103] Increased HDL catabolism [104] Enhanced MDSC survival [105] |
PLA2 | ↑ | Hydrolyzes phospholipids to generate an FFA and lysophospholipid | Elevated lipoprotein-associated levels independent predictor of mortality in sepsis [106] Mainly mobilizes AA [107] |